Osimertinib Achieves Extended Disease-Free Survival in EGFR-Mutant NSCLC
September 21st 2020In patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection, treatment with osimertinib reduced the risk for central nervous system death or progression by 82%, findings presented during the EMSO Virtual Congress 2020.
Read More
Palbociclib/Fulvestrant Prolongs PFS in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer
September 21st 2020Patients with endocrine-sensitive hormone receptor–positive, HER2-negative metastatic breast cancer, treated with Frontline fulvestrant in combination with palbociclib experienced improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone, achieving the primary end point of the phase 2 FLIPPER trial.
Read More
Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer
September 21st 2020Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.
Read More
Pembrolizumab Plus Chemotherapy Enters Frontline Treatment Landscape of Advanced Esophageal Cancer
September 21st 2020In the phase 3 KEYNOTE-590 clinical trial, frontline pembrolizumab plus chemotherapy demonstrated a significant improvement in overall survival, progression-free survival, and objective response rates versus chemotherapy only in patients with locally advanced unresectable or metastatic esophageal cancer, result presented during the 2020 ESMO Virtual Congress show.
Read More
Survival Improvement Observed with Cemiplimab in Frontline Advanced PD-L1+ NSCLC
September 21st 2020In the phase 3 EMPOWER-Lung 1 trial, patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells, had a significant improvement in overall survival and progression-free survival with cemiplimab-rwlc monotherapy compared with platinum-doublet chemotherapy.
Read More
Nivolumab Plus Chemotherapy Extends PFS With Durable Responses in Gastric/GEJ Cancers
September 21st 2020In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.
Read More
Non-Superiority of Weekly Dose-Dense Chemotherapy Versus SOC Shown in Epithelial Ovarian Cancer
September 21st 2020Patients with epithelial ovarian cancer treated with weekly dose-dense chemotherapy in the ICON8 clinical trial experienced similar progression-free survival and overall survival as patients treated with the standard-of-care.
Read More
Survival Improved With Tucatinib Regimen in HER2-Positive Metastatic Breast Cancer
September 21st 2020Statistically significant and clinically meaningful improvements in both progression-free survival and overall survival were observed with the addition of tucatinib to trastuzumab and capecitabine as treatment of patients with HER2-positive metastatic breast cancer, irrespective of the presence of brain metastases.
Read More
Adding Bevacizumab to Osimertinib Failed to Improve PFS in EGFR T790M+ Lung Cancer
September 21st 2020Osimertinib plus bevacizumab did not lead to a prolonged progression-free survival compared with osimertinib alone as treatment of patients with advanced adenocarcinoma harboring EGFR T790M.
Read More
Tisotumab Vedotin Shows Promise in Recurrent/Metastatic Cervical Cancer
September 21st 2020In the phase 2 single-arm innovaTV 204 trial, treatment with tisotumab vedotin led to an objective response rate (ORR) of 24% (95% CI, 15.9%-33.3%) in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab (Avastin). The encouraging result was announced during a presentation at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress.
Read More
Lenvantinib and Pembrolizumab Induce Responses Across Advanced Solid Tumors
September 21st 2020The combination of lenvatinib and pembrolizumab demonstrated responses in patients with previously treated advanced solid tumors in findings presented at the 2020 ESMO Virtual Congress from the phase 2 LEAP-005 trial.
Read More
Ipatasertinib Combo Prolongs PFS in PTEN-Loss mCRPC
September 21st 2020A primary analysis from the phase 3 IPATential150 trial demonstrated the benefit of the addition of ipatasertib to abiraterone acetate and prednisone in the treatment of patients with metastatic castration-resistant prostate cancer with PTEN loss, according to results presented at the 2020 ESMO Virtual Congress.
Read More
Ewing Sarcoma May Benefit From Regorafenib Therapy
September 20th 2020As compared with placebo, regorafenib induced favorable progression-free survival rates at 24 weeks versus placebo in patients with Ewing sarcoma in the phase 2 REGOBONE study. Despite this, the trial failed to meet its primary end point of non-progression at 8 weeks, according to findings presented at the European Society of Medical Oncology Virtual Congress 2020.
Read More
Larotrectinib Elicits Rapid, Durable Responses in TRK Fusion-Positive Solid Tumors
September 20th 2020Larotrectinib demonstrated rapid and durable as treatment of patients with TRK fusion-positive solid tumors, as well as a favorable long-term toxicity profile, according to an expanded pooled analysis from 3 clinical trials.
Read More
OS With Olaparib Bests Androgen Receptor Inhibitors in Certain Men With mCRPC
September 20th 2020Updated findings from the randomized, open-label phase 3 PROfound trial indicate that olaparib induces a significantly longer duration of overall survival versus enzalutamide or abiraterone plus prednisone in metastatic castration-resistant prostate cancer tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and disease that has progressed during previous treatment with a next-generation hormonal agent.
Read More
Responses, Favorable Safety Profile Reported for Amivantamab Plus Lazertinib in EGFR+ NSCLC
September 20th 2020Findings from the phase 1 CHRYSALIS study showed that patients with advanced EGFR-mutant non–small cell lung cancer who were treatment naïve or resistant to osimertinib therapy had high response rates when treated with the combination of amivantamab and lazertinib. Results also demonstrated a favorable safety profile for the regimen, according to results reported at the ESMO Virtual Congress 2020.
Read More
EGFR+ NSCLC Treated in the Frontline With Osimertinib/Apatinib Combination Has PFS Improvement
September 20th 2020The combination of apatinib and gefitinib demonstrated the feasibility of dual VEGFR/EGFR inhibition in patients with advanced EGFR-mutant non–small cell lung cancer, according to progression-free survival results of the phase 3 ACTIVE trial that were reported at the ESMO Virtual Congress 2020.
Read More
Positive safety, pharmacokinetic, and pharmacodynamic data were reported for the first-in-human phase 1 dose-escalation trial of MGD019 during the European Society for Medical Oncology Virtual Congress 2020 as well as preliminary antitumor activity in select tumor types.
Read More
Intracranial Responses Are Induced With Entrectinib in NTRK+ Tumors
September 20th 2020Patients with NTRK fusion–positive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib, according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.
Read More
Phase 3 Trial Results Do Not Support PORT in Resected Stage IIIAN2 NSCLC
September 20th 2020Patients with completely resected stage IIIAN2 non–small cell lung cancer should not be recommended for post-operative radiotherapy, according to results from the phase 3 LungART trial that were presented during the ESMO Virtual Congress 2020, due to nonstatistically significant increase in disease-free survival versus those treated in the control group.
Read More
In High-Risk Early Breast Cancer, Risk of Recurrence Is Reduced With Abemaciclib
September 20th 2020Findings from the phase 3 monarchE trial reported at the ESMO Virtual Congress 2020 showed that the risk of invasive disease with abemaciclib plus endocrine therapy was significantly reduced versus endocrine therapy alone in patients with high-risk early hormone receptor-positive, HER2-negative breast cancer.
Read More
Responses Significantly Improved With Atezolizumab Regimen in Triple-Negative Breast Cancer
September 20th 2020The pathologic complete responses were significantly improved with neoadjuvant atezolizumab in combination with nab-paclitaxel plus doxorubicin and cyclophosphamide compared with placebo and chemotherapyin patients with stage 2 or stage 3 triple-negative breast cancer.
Read More
Significant Benefit Observed in HR+/HER2- Breast Cancer With Dose-Dense iddEPC
September 20th 2020Patients with HR-positive, HER2-negative breast cancer experienced significant benefit when treated with neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide.
Read More
Survival Improved With HAIC Over Standard TACE in Unresectable HCC
September 20th 2020A significant improvement in overall survival was observed with the addition of hepatic arterial infusion chemotherapy to oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Read More
Abemaciclib Doublet Demonstrates OS Benefit in HR+, HER2- Metastatic Breast Cancer
September 20th 2020Abemaciclib in combination with tamoxifen led to an improvement in overall survival compared with abemaciclib alone in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Notably, the benefit of the combination was observed across all subgroups in the study, according to findings from the final OS analysis of the nextMONARCH trial presented during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Frontline Lorlatinib Leads to Better Outcomes Compared With Crizotinib in Advanced ALK+ NSCLC
September 20th 2020According to results from the phase 3 CROWN trial, the third-generation ALK tyrosine kinase inhibitor loralitinib achieved a significant improvement in progression-free survival as well as higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.
Read More